The share of clinical stage biotechnology Five main therapies (Nasdaq stock code: FPRX) The 364% gain in premarket trading on Wednesday morning was jaw-dropping. Due to the positive results of the mid-term trial of the gastric cancer drug candidate bematuzumab, the biotech company’s stock soared.
Specifically, the five Primes and partners Zai Lab (Nasdaq: ZLAB) It is reported that the combination of benatuzumab and mFOLFOX6 chemotherapy has three efficacy endpoints in patients with fibroblast growth factor receptor 2b positive and HER2 negative (median progression-free survival, median overall survival and overall response Rate) defeated placebo and mFOLFOX6 as first-line advanced gastric cancer or gastroesophageal junction cancer. Zai Lab has the development and commercial rights of the drug in China through a license agreement with Five Prime.
Bematuzumab may still have to pass in a larger critical phase trial to get approval in China or the United States. However, first-line gastric cancer drugs undoubtedly have huge commercial potential. After all, gastric cancer is one of the most common types of malignant tumors and the leading cause of death worldwide. With this background in mind, it is not surprising that investors poured into this small biotech stock this morning.
How to do
According to yesterday’s press release, Five Prime and Zai Lab also pointed out that bematuzumab may be used in a series of solid tumors (such as squamous non-small cell lung cancer, triple negative breast cancer, ovarian cancer, pancreatic cancer and intrahepatic bile duct cancer). .
This means that bematuzumab may prove to be a franchise cancer drug. Since such rare gems are rarely ignored by large pharmaceutical companies, the “Five Prime” (Five Prime) may soon rise in the acquisition of rumored factories. stay tuned.